Metformin is a widely used oral drug for type 2 diabetes and its antitumor effects have got
much more attentions recently. It has been shown that metformin exerts anti-cancer activities
in several cancers, including primary liver cancer. In this phase II study, safety and
efficacy of the combination of metformin and sorafenib will be evaluated in patients with
advanced hepatocellular carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Collaborators:
First Affiliated Hospital of Harbin Medical University Fudan University Harbin Medical University Liaoning Tumor Hospital & Institute Shanghai Zhongshan Hospital